Literature DB >> 20505683

Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns.

Beom Hee Lee1, Sun Hee Heo, Gu-Hwan Kim, Jung-Young Park, Woo-Shik Kim, Duk-Hee Kang, Kyung Hoon Choe, Won-Ho Kim, Song Hyun Yang, Han-Wook Yoo.   

Abstract

Fabry disease is caused by an alpha-galactosidase A (GLA) deficiency. In this study, we identified 28 unrelated Korean families with Fabry disease with 25 distinct mutations in the GLA gene including six novel mutations (p.W47X, p.C90X, p.D61EfsX32, IVS4(-11)T>A, p.D322E and p.W349). Notably, five subjects from four unrelated families carried the p.E66Q variant, previously known as a pathogenic mutation in atypical Fabry disease. Among these patients, only one had proteinuria and two had hypertrophic cardiomyopathy without any other systemic manifestation of Fabry disease. Substantial residual GLA activity was shown both in the leukocytes of p.E66Q patients (19.0-30.3% of normal activity) and in transiently overexpressed COS-7 cells (43.8 + or - 3.03% of normal activity). Although GLA harboring p.E66Q is unstable at neutral pH, the enzyme is efficiently expressed in the lysosomes of COS-7 cells. The location of p.E66 is distant from both the active site and the dimer interface, and has a more accessible surface area than have other mutations of atypical Fabry disease. In addition, the allele frequency of p.E66Q determined in 833 unrelated Korean individuals was remarkably high at 1.046% (95% confidence interval, 0.458-1.634%). These results indicate that p.E66Q is a functional polymorphism rather than a pathogenic mutation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505683     DOI: 10.1038/jhg.2010.58

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  19 in total

Review 1.  Fabry disease: a rare cause of neuropathic pain.

Authors:  Marieke Biegstraaten; Gabor E Linthorst; Ivo N van Schaik; Carla E M Hollak
Journal:  Curr Pain Headache Rep       Date:  2013-10

2.  Prevalence of Fabry disease and GLA c.196G>C variant in Japanese stroke patients.

Authors:  Kiyoshiro Nagamatsu; Yoshiki Sekijima; Katsuya Nakamura; Kimitoshi Nakamura; Kiyoko Hattori; Masao Ota; Yusaku Shimizu; Fumio Endo; Shu-Ichi Ikeda
Journal:  J Hum Genet       Date:  2017-03-09       Impact factor: 3.172

3.  FabryScan: a screening tool for early detection of Fabry disease.

Authors:  Kathrin Arning; Dennis Naleschinski; Rainer Maag; Marieke Biegstraaten; Peter Kropp; Jürgen Lorenzen; Carla E M Hollak; Ivo N van Schaik; Pontus Harten; Rainald A Zeuner; Andreas Binder; Ralf Baron
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

4.  Role of the p.E66Q variant of GLA in the progression of chronic kidney disease.

Authors:  Hirofumi Watanabe; Shin Goto; Akinori Miyashita; Hiroki Maruyama; Minako Wakasugi; Akio Yokoseki; Ryozo Kuwano; Ichiei Narita
Journal:  Clin Exp Nephrol       Date:  2014-04-10       Impact factor: 2.801

5.  Mutation spectrum of α-Galactosidase gene in Japanese patients with Fabry disease.

Authors:  Masahisa Kobayashi; Toya Ohashi; Eiko Kaneshiro; Takashi Higuchi; Hiroyuki Ida
Journal:  J Hum Genet       Date:  2019-04-15       Impact factor: 3.172

6.  Prevalence of Fabry disease in dialysis patients: Japan Fabry disease screening study (J-FAST).

Authors:  Osamu Saito; Eiji Kusano; Tetsu Akimoto; Yasushi Asano; Teruo Kitagawa; Ken Suzuki; Nobuyuki Ishige; Takashi Akiba; Akira Saito; Eiji Ishimura; Motoshi Hattori; Akira Hishida; Chu Guili; Hiroki Maruyama; Masahisa Kobayashi; Touya Ohashi; Ichiro Matsuda; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2015-07-22       Impact factor: 2.801

7.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

8.  Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.

Authors:  Hiroki Maruyama; Takuma Takata; Yutaka Tsubata; Ryushi Tazawa; Kiyoe Goto; Jun Tohyama; Ichiei Narita; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

9.  Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.

Authors:  Hideaki Sueoka; Junji Ichihara; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba
Journal:  PLoS One       Date:  2015-05-12       Impact factor: 3.240

10.  A Novel Frameshift Mutation of Galactosidase-alpha in Fabry Disease Restricted to Dermatologic Manifestations.

Authors:  Dae Hun Kim; Soo Yeon Kim; Myung Im; Young Lee; Young Joon Seo; Jeung Hoon Lee
Journal:  Ann Dermatol       Date:  2013-02-14       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.